XYNTHA DUAL CHAMBER
XYNTHA is indicated for the control and prevention of haemorrhagic episodes in patients with haemophilia A, including control and prevention of bleeding in surgical settings. XYNTHA does not contain von Willebrand factor and should not be used by patients with von Willebrand’s disease.
XYNTHA dual chamber is the latest innovation from Pfizer. It’s the only haemophilia device in New Zealand that’s preloaded with both factor VIII and diluent for quick and convenient treatment.
Available in an all-inclusive kit, the XYNTHA dual chamber syringe features an innovative all-in-one convenient design that eliminates the transfer step for ease of reconstitution. XYNTHA, it’s ready to go when you are.